258 related articles for article (PubMed ID: 26879734)
1. The Long-term Disease-specific Mortality of Low-risk Localized Prostate Cancer: A Prospective Population-based Register Study Over Two Decades.
Klaff R; Rosell J; Varenhorst E; Sandblom G
Urology; 2016 May; 91():77-82. PubMed ID: 26879734
[TBL] [Abstract][Full Text] [Related]
2. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
Adolfsson J; Tribukait B; Levitt S
Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
D'Amico AV; Renshaw AA; Sussman B; Chen MH
JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen levels as a predictor of lethal prostate cancer.
Fall K; Garmo H; Andrén O; Bill-Axelson A; Adolfsson J; Adami HO; Johansson JE; Holmberg L;
J Natl Cancer Inst; 2007 Apr; 99(7):526-32. PubMed ID: 17405997
[TBL] [Abstract][Full Text] [Related]
5. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
6. 20-year outcomes following conservative management of clinically localized prostate cancer.
Albertsen PC; Hanley JA; Fine J
JAMA; 2005 May; 293(17):2095-101. PubMed ID: 15870412
[TBL] [Abstract][Full Text] [Related]
7. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
8. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
9. Short- and long-term mortality with localized prostate cancer.
Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
[TBL] [Abstract][Full Text] [Related]
10. Natural history of early, localized prostate cancer: a final report from three decades of follow-up.
Popiolek M; Rider JR; Andrén O; Andersson SO; Holmberg L; Adami HO; Johansson JE
Eur Urol; 2013 Mar; 63(3):428-35. PubMed ID: 23084329
[TBL] [Abstract][Full Text] [Related]
11. Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL.
Ladjevardi S; Berglund A; Varenhorst E; Bratt O; Widmark A; Sandblom G
BJU Int; 2013 Mar; 111(3):381-8. PubMed ID: 22758210
[TBL] [Abstract][Full Text] [Related]
12. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
13. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden.
Johansson JE; Holmberg L; Johansson S; Bergström R; Adami HO
JAMA; 1997 Feb; 277(6):467-71. PubMed ID: 9020270
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
15. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
[TBL] [Abstract][Full Text] [Related]
16. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
J Clin Oncol; 2003 Jun; 21(11):2163-72. PubMed ID: 12775742
[TBL] [Abstract][Full Text] [Related]
17. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
[TBL] [Abstract][Full Text] [Related]
18. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
[TBL] [Abstract][Full Text] [Related]
20. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
